Clearside Biomedical (CLSD) shares fell 31% in recent Friday trading after downgrades by at least five analysts.
Stifel downgraded the stock to neutral from buy and cut its price target to $2 from $8. Chardan lowered its rating to neutral from buy and withdrew its $6 price target. HC Wainwright, Needham and Jones Trading also issued downgrades.
Clearside's intraday volume topped 3.08 million shares versus the daily average of 238,151.
Price: 0.41, Change: -0.19, Percent Change: -31.37